跳至主要内容
临床试验/NL-OMON50717
NL-OMON50717尚未招募4 期

SUSTAINED RESPONSE TO NUCLEO(S)TIDE ANALOGUES FOR CHRONIC HEPATITIS B: SNAP STUDY - SNAP

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 200 人开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
尚未招募
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Age 18 * 65 years
  • Treatment with entecavir or tenofovir
  • Previously HBeAg positive patients: stable HBeAg seroconversion (confirmed
  • HBeAg seroconversion at least 6 months apart) with at least 12 months of
  • subsequent consolidation therapy with HBV DNA <80 IU/mL
  • HBeAg negative patients: at least 3 years of continuous viral suppression (HBV
  • DNA <80 IU/mL)
  • Fibroscan value <7.0 at baseline

排除标准

  • * History of liver biopsy with advanced fibrosis or cirrhosis (F3 or F4)
  • * History of hepatic decompensation
  • * (history of) hepatocellular carcinoma
  • * Other active malignancy
  • * (planned) treatment with immunosuppressive agents
  • * (planned) pregnancy
  • * Coinfection with HIV, HCV, HDV
  • * Concomitant liver condition that may influence liver chemistry (such as
  • Gilbert*s syndrome). Defined as baseline ALT > 2x upper limit of normal, and/or
  • bilirubin > 1x upper limit of normal.
  • * Other indication for continued nucleo(s)tide analogue therapy
  • * Expected noncompliance to follow-up
  • * Treatment with medication that increases INR (such as vitamin K antagonists)
  • * Unwillingness to refrain from sexual activity without condom with partners
  • who are not vaccinated against hepatitis B virus

研究者

相似试验